Citation Tools
PDFImmunotherapy biomarkers
Original research
Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy